AstraZeneca Rebuilds Its R&D, With Payers In Mind
Executive Summary
When Martin Mackay joined AstraZeneca PLC as president, global research & development, from Pfizer Inc. one year ago, one of his objectives was to "put AstraZeneca's R&D back on the map."
You may also be interested in...
AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.
Biopharma In 2011: A Year Of Transition
If 2010 was the year when pharma introduced new models, 2011 was the year it discovered that executing on its plans required a new mindset. There was a realization that pharma input and capital were required at the earliest stages of company creation. Innovation remained the order of the day, though pharma’s attempts to innovate looked strikingly similar to one another. We continued to see risk-sharing deal structures, emphasis on emerging markets, ongoing externalization and the biotech-ification of pharma, and stronger emphasis on “unmet medical need. Pharma also did more to work with VCs, payors, generics companies, and each other. The year saw a recovery in US drug approvals and launches, but the high prices associated with some of those new therapies and austerity in Europe also shed light on the health technology assessment-dominated future that likely faces most markets, including the US.
China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way
Chinese startup Hua Medicine kicks off its in-licensing strategy with an IND-ready glucokinase activator from Roche.